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Abstract: Spindle toxins belong to the most potent antineoplastic agents because of inhibition of mi-
tosis leading to interruption of the regular cell cycle and occasionally to cell death through apoptosis.
The epothilones belong to the group of microtubule-stabilizing chemotherapeutics. They show promising
antitumor effect in refractory and metastatic tumors in humans and toxicity profile is considered more
favorable than the one of the potent group of the taxanes. The use of taxanes is limited in veterinary
medicine due to hypersensitivity reactions. Aim of this study was to evaluate patupilone, an epothilone
B, for use in dogs. The in vitro part assessed inhibition of proliferation in canine cell lines, the in vivo
part evaluated the toxicity profile and maximally tolerated dose in a phase I dose-escalating trial in 21
dogs with spontaneously occurring treatment refractory tumors. In vitro, canine hemangiosarcoma and
lymphoma cells showed inhibition of proliferation already at low doses. In vivo, dose-limiting toxicities
consisted of diarrhea and anorexia. Maximally tolerated dose for two intravenous patupilone adminis-
trations once weekly in dogs with spontaneously occurring tumors was 2.76 mg/m2. Three of eleven
dogs receiving more than one treatment cycle showed partial remission in the short period of observa-
tion. Spindeltoxine gehören zu den potentesten Substanzen im Kampf gegen Krebs, da sie die Mitose
hemmen und zu einem Zellzyklusunterbruch und Apoptose führen können. Epothilone sind Mikrotubuli-
stabilisierende Chemotherapeutika, welche in der Humanmedizin vielversprechende Resultate bei metas-
tatischen Tumoren erzielt haben und weniger Toxizität auslösen als die sehr potente Gruppe der Taxane.
Der Gebrauch von Taxanen in der Veterinärmedizin ist limitiert durch das Auftreten von Hypersensi-
tivitätsreaktionen. Ziel dieser Studie war die Verabreichung von Patupilone, einem Epothilone B, beim
Hund. Der in vitro Teil der Studie befasste sich mit der Proliferationshemmung in kaninen Zelllinien,
während der in vivo Teil mit Dosiseskalation das Toxizitätsprofil und die maximal tolerierte Dosis bei 21
Hunden mit spontan aufgetretener Tumorerkrankung auswertete. Kanine Hämangiosarkom- und Lym-
phomzellen zeigten bereits bei niedriger Dosierung eine Proliferationshemmung. Die dosis-limitierende
Toxizität erwies sich als Durchfall und Anorexie. Die maximal tolerierte Dosis für zwei intravenöse Gaben
einmal wöchentlich bei Hunden mit spontaner Tumorerkrankung war 2.76 mg/m2. Drei Hunde, welche
mehr als einen Zyklus erhalten hatten zeigten eine partielle Remission.
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Abstract: 
Background: The epothilones are microtubule-stabilizing agents with promising antitumor 
effect in refractory and metastatic tumors in humans. The toxicity profile is considered more 
favorable than in taxanes. The safety of epothilone B (patupilone) has not been evaluated in 
tumor-bearing dogs. 
Objectives: To evaluate the inhibition of proliferation in canine tumor cells after patupilone 
treatment. To assess toxicity profile and maximally tolerated dose of patupilone in dogs with 
refractory tumors. 
Animals: Twenty client-owned dogs with various malignancies. 
Methods: The inhibition of proliferation was assessed with a proliferation assay in vitro in 
canine hemangiosarcoma and lymphoma cell lines. In the prospective clinical study, dogs 
received patupilone intravenously once a week for two treatments (= one treatment cycle). 
Dose was escalated with three dogs per cohort and 20% increments. Adverse effects were 
graded according to the VCOG-CTCAE v1.0.  
Results: Both canine cell lines were sensitive to patupilone with approximately 50% decrease 
  
of proliferative activity at 0.2-1 nM. In vivo, dose-limiting adverse effects occurred at 3.3 
mg/m
2
; main adverse effects were diarrhea, anorexia, vomiting, and nausea. Neither 
neutropenia nor peripheral neuropathy was observed. Maximally tolerated dose for two 
patupilone administrations once weekly IV is 2.76 mg/m
2
. 3/11 dogs receiving more than one 
treatment cycle showed partial remission in the short period of observation. 
Conclusions and Clinical Importance: Canine tumor cells show inhibition of proliferation 
to patupilone in vitro. Clinically, a dose of 2.76 mg/m
2 
IV is well tolerated in dogs with 
spontaneously occurring tumors.
  
Epothilones are potent nontaxoid microtubule-stabilizing agents (MSA) of bacterial origin 
sharing the binding site on β-tubulin with the taxanes, which belong to the most potent 
antineoplastic agents.
1, 2
 MSA interfere with microtubule function in the proliferating cell by 
preventing the shortening of microtubules, resulting in a permanent or transient cell cycle arrest 
at the G2/M-phase which leads to apoptosis.
1, 2
 Ixabepilone
a
 is the first compound of the 
epothilones to be approved as monotherapy or in combination with capecitabine for the treatment 
of women with metastatic breast cancer and demonstrates activity in tumors that show resistance 
towards anthracycline and taxane standard therapy.
2, 3
 Compared to the taxanes, epothilones are 
described to be more potent and possess several advantages such as increased solubility, low 
susceptibility to drug efflux transporters (for example p-glycoprotein-mediated chemoresistance), 
and a more tolerable toxicity profile in human patients, which favors their development and 
makes them promising agents for further use in dogs as well.
2, 4
 Patupilone (EPO906) is a natural, 
water-soluble epothilone B extracted from mycobacterium sorangium cellulosum and is the most 
active variant of the natural epothilones. The efficacy of patupilone is based on not only targeting 
tumor cells, but also the vasculature and angiogenesis of solid tumors.
5, 6, 7
 Patupilone was tested 
as a phase III monotherapy agent against ovarian cancer in human patients and other epothilones 
are currently undergoing a wide spectrum of single and combined treatment modality in phase II 
and phase III studies (e.g. for recurrent glioblastoma multiforme, breast cancer brain metastases, 
prostate, cervical, renal cell, gastric and lung tumors, as well as non-Hodgkin’s lymphoma).8, 9, 10, 
11, 12
  
In order to introduce this promising antineoplastic substance group into veterinary medicine, the 
objectives of this study were 1) to evaluate, whether patupilone shows in vitro efficacy against 
canine tumor cell lines and 2) to determine the adverse effect (AE) profile and the maximally 
  
tolerated dose (MTD) for IV administration in dogs with various spontaneously occurring, 
treatment-refractory tumors.  
 
Material and Methods: 
In Vitro Study: 
Canine Tumor Cell Lines. A canine malignant T-cell lymphoma cell line (CL-1) and a canine 
hemangiosarcoma cell line were used.
13, 14 
CL-1 cells were cultured in RPMI 1640 with 1% (v/v) 
stable glutamine
b
, 10% (v/v) fetal bovine serum
c
, and 1% (v/v) penicillin-streptomycin
d
. 
Hemangiosarcoma cells were cultured in D-MEM/F-12 containing 1% (v/v) L-glutamine
e
, 10% 
(v/v) fetal bovine serum
f
, and 1% (v/v) antibiotic-antimycotic
g
 solution. All cells were incubated 
at 37°C in a humified incubator with 5% v/v CO2.  
Study Drug. Patupilone (epothilone B) was provided by Novartis Pharma, Basel, Switzerland. In 
order to obtain the stock solution, patupilone was dissolved in DMSO to a concentration of 1 mM 
and further stored at 2-8°C. Immediately before addition to cell lines, stock solution was diluted 
in culture medium in order to achieve the appropriate concentrations. Final DMSO concentrations 
used in the assays were in the nanomolar range (≤ 0.0001%) and were considered to be 
negligible. 
Cell Proliferation Assays. The proliferative activity of tumor cells was assessed with the 
colorimetric alamarBlue
®
 assay
h
 according to the protocol of the manufacturer. AlamarBlue
®
 
assesses metabolic activity of living cells by measurement of spectral absorption. Proliferation 
assays were performed in 96-well plates with 1 x 10
4
 and 0.75 x 10
4
 cells/well for CL-1 and 
hemangiosarcoma cell lines, respectively. Prior to the experiment, optimization assays (cell 
number) were performed to optimize the absorbance reading for spontaneous proliferation (i.e. 
proliferation at 0 nM). Each well contained 100 μl of cell suspension in the concentration 
  
mentioned above, wells used as blank controls contained 100 μl of media only. After a 24 hour 
incubation period, the cells were treated with 10 μl of increasing concentrations of patupilone, 
control cells (0 nM) and blank wells (media only) were treated with 10 μl of plain medium. 
Absorbance was measured in triplicates before and 24, 48, and 72 hours after patupilone 
treatment at 570 and 630 nm using the spectrophotometer SpectraMax
®
 Plus
384
 Absorbance 
Microplate Reader
i
 and SoftMax
®
 Pro 4.8 Software
j
 after a 6-hour incubation period of 
alamarBlue
®
 dye. Background absorbance of cell media was subtracted. All assays were repeated 
as independent experiments at least thrice. The approximate 50% decrease of proliferative 
activity was derived from graphical plotting of data. 
In Vivo Study: 
Patient Eligibility Criteria. Dogs presented to the Vetsuisse Faculty, University of Zurich, 
Switzerland with histologically or cytologically confirmed neoplastic disease were prospectively 
enrolled in this study if they were refractory to standard of care treatment, if the owner declined 
other treatment, or if no established standard of care existed. In order to meet inclusion criteria, 
dogs required a modified Karnofsky’s score of ≤1, adequate hematologic, renal, and hepatic 
function and absence of any serious systemic disorder incompatible with the study at the 
discretion of the investigators.
15
 Prior chemotherapy treatment had to be terminated at least two 
weeks before start of the study. Written owner consent was obtained and the study was approved 
by the Animal Ethics Council of the Canton of Zurich, Switzerland.  
Study Design and Drug Administration. This trial was a phase I dose-escalating, open-label 
assessment of adverse effects (AE) of patupilone in client-owned dogs with spontaneously 
occurring tumors. Safety was assessed on enrolment of at least three dogs into dose-escalating 
cohorts using a traditional 3+3 design.
16, 17
 Escalation was performed according to Vail
17
 where 
the dose was escalated if none of three dogs of one dose cohort developed dose-limiting AE as 
  
defined according to the VCOG-CTCAE v1.0.
18
 If one of the three dogs of a cohort experienced 
a dose-limiting AE or if the second treatment had to be delayed ≥5 days due to grade 2 toxicosis, 
then at least three more dogs were included at the same dose level. Dose escalation was stopped, 
if two or more dogs of a cohort of three, or an extended cohort of six patients, respectively, 
developed dose-limiting AE or a treatment delay. This dose level was the maximally 
administered dose. The maximally tolerated dose (MTD) was defined as the highest dose level in 
which no more than one of six dogs develops a dose-limiting AE.
17
 Escalation steps occurred in 
increments of 20% of the previous dose. Starting dose was 1.6 mg/m
2
, based on 50% of the MTD 
of experimental beagle dog data.  
Treatment schedule consisted of two IV administrations of the drug once weekly (= one treatment 
cycle). In turn, dogs were evaluated every week for adverse effects and tumor response. If no 
progression was noted, treatment with patupilone was continued at the same dose level.  
Patupilone (epothilone B) for in vivo use was provided by Novartis Pharma, Basel, Switzerland 
as vials concentrate liquid of 10 mg/4 mL. In order to prepare the epothilone B for 
administration, the concentrate was diluted with normal saline, to obtain a concentration of 1 
mg/mL. The calculated dose was given via IV infusion in parallel to 100 mL 0.9% saline over a 
10-20-minute interval.  
Supportive care (e.g. antiemetics, antidiarrheals) was administered after occurrence of AE and 
was provided prophylactically after the next administration of drug. Medication for disease 
unrelated co-morbidity or further supportive care including steroids and non steroidal anti-
inflammatory drugs (NSAIDs) that had been administered at study entry and under which the 
dogs had shown progressive disease prior to study entry were continued. Antibiotics were 
prescribed in case of ulceration of tumor, analgesics for tumor-associated pain were allowed, and 
dogs with mast cell tumors at risk of histamine release received H1- and H2-blocking agents. 
  
Assessment of Adverse Effects. Dogs were evaluated for signs of intoxication weekly before 
each treatment, and one week after the last chemotherapy. Evaluation of severity of toxicoses to 
determine MTD was done after the first and second patupilone dose only. AE were monitored by 
performing a physical examination, complete blood count (CBC) and serum biochemistry at each 
scheduled appointment and by grading the dogs according to the Modified Karnofsky’s 
Performance Criteria.
15
 Owners were asked to keep a log at home. Blood results and signs of AE 
were graded according to the VCOG-CTCAE v1.0.
18
 Unacceptable AE leading to discontinuation 
of the trial was defined as ≥ grade 3 toxicosis, except hematological AE, where ≥ grade 4 was 
considered unacceptable. Because this trial included heavily pretreated patients with an advanced 
stage of disease, a baseline status using the same criteria was recorded for each dog before start 
of the trial. 
Tumor Response Assessment. Due to the dose-escalating nature of this trial, response to 
treatment was only a secondary goal. Tumor size (locoregional and systemic) was assessed at 
study entry, before each drug administration and one week after the last treatment by means of 
caliper measurements and additional diagnostic imaging according to the tumor. In non-
metastatic tumors, clinical staging (thoracic radiographs, abdominal ultrasound) was performed at 
study entry and comparable re-evaluations took place after two and four patupilone 
administrations to exclude disease progression by means of systemic extension. Response was 
assessed as follows: in dogs with multicentric lymphoma, criteria according to VCOG consensus 
document for peripheral nodal lymphoma in dogs were used.
19
 Lymph nodes were measured 
using calipers and the mean sum of the longest diameter of a maximum of five target lesions was 
calculated. In dogs with other solid tumors, response was measured according to the revised 
RECIST guideline v1.1.
20
 The sum of diameters of all target lesions was calculated and reported 
as the baseline sum diameter. According to both guidelines, responses were considered to be 
  
complete if all target lesions had disappeared (or lymph nodes were of normal size, respectively), 
partial (PR) if a 30% decrease of the sum of target lesion diameters occurred, or progressive (PD) 
if new lesions occurred or if there was an increase of at least 20% in the sum of target lesion 
diameters, taking as reference the smallest sum on study.
21
 Dogs that neither showed sufficient 
shrinkage to qualify for PR nor sufficient increase to qualify for PD were considered to have 
stable disease (SD).
19, 20
  
 
Results: 
In Vitro Study: 
Cell Proliferation Assays. In the two canine cell lines tested, 50% decrease of proliferative 
activity was found to be in the range of 1 nM in canine hemangiosarcoma and 0.2 nM in 
malignant lymphoma cells (figure 1). Compared to drug sensitive human cell lines, the tested cell 
lines showed sensitivity to patupilone.
22, 23
 
 
  
 
Figure 1: Proliferation activity after patupilone treatment was assessed over 72 hours using the 
alamarBlue
®
 assay. Canine hemangiosarcoma (A) and malignant lymphoma cells (B) showed a 
50% decrease of proliferative activity at 1 and 0.2 nM, respectively. Both graphs show a single 
representative experiment with inclusion of standard deviation. A.u.: artificial unit. 
 
In Vivo Study: 
Patient Characteristics. A total of 20 client-owned dogs were included in the study between July 
2009 and October 2011. Patient population consisted of dogs of various breeds: mixed breed 
(n=6), boxer (n=3), golden retriever (n=2), American pitbull, Jack Russell terrier, Australian, 
Belgian, German shepherd, Doberman pinscher, greater Swiss mountain dog, rottweiler, and 
standard poodle (one each). Median age upon study entry was 8.75 years (range 6-14 years) and 
median weight 28.4 kg (range 5.7-51.4 kg). Four dogs were intact females, two intact males, ten 
were spayed females and four castrated males. Different types of tumors were included; the most 
  
common primary tumors were malignant mammary carcinomas (n=6), and malignant 
multicentric lymphoma (n=6); two of the mammary tumors were diagnosed as anaplastic 
mammary adenocarcinoma. Other tumors included mast cell tumors (n=3), prostate carcinoma 
(n=2), anal gland adenocarcinoma, oral malignant melanoma, and cardiac hemangiosarcoma (one 
each). The majority of dogs had received prior treatment with either chemotherapy (n=10), 
surgery (n=4), surgery and chemotherapy (n=1) or radiation therapy (n=1). All but one dog had 
measurable disease at the onset of patupilone treatment. 13/20 (65%) showed macroscopic local 
or locoregional disease (one distant metastasis), 6/20 (30%) had multicentric malignant 
lymphoma and one dog (5%) showed microscopic disease after surgery of a large invasive 
mammary carcinoma. All six dogs with malignant lymphoma showed multicentric involvement 
stage IV-V, substage a-b disease and clinical resistance towards several previous chemotherapy 
protocols. Two dogs showed T-cell, two B-cell, one null-cell lymphoma, and in one dog 
immunophenotyping was not performed. 
Drug Administration. Patients were divided into six different dose groups from 1.6 to 3.3 mg/m
2
 
with increments of 20%, except in the dose group 6 (see table 1). At the starting dose of 1.6 
mg/m
2
 only one dog was included; due to rapid disease progression and no drug-related AE, the 
second dog was treated with the next higher dose. The other groups included at least three dogs 
per dose level, with additional three (confirmatory) patients at the MTD level. In total, 62 
patupilone doses were administered, with a median of three per dog (range 1-7). Eighteen dogs 
received one cycle of patupilone (as planned) and eleven of these continued treatment with the 
study drug. Two dogs received one patupilone treatment only, due to grade 2 AE and owner’s 
decline for further treatment in one dog, and grade 3 AE and exclusion of the study in another 
dog. Seven dogs received concurrent NSAIDs and eight received steroids.  
  
* Dose was reduced by 10% to approach the optimal dose more precisely. 
** of which 2 were grade 2 leading to a relevant treatment delay of  ≥5 days 
*** of which 1 was grade 2 leading to a relevant treatment delay of  ≥5 days 
Assessment of Adverse Effects: 
Metabolic AE were evaluable after 60 of the 62 drug administrations; data of all other AE was 
assessable after every patupilone administration.  
Metabolic: Hematological and serum biochemical AE were mild, as summarized in table 2. In 
9/13 dogs with anemia (17 administrations), grade 1 toxicosis was already present at study entry 
with no change during the study. Grade 1-2 thrombocytopenia occurred in three dogs with 
advanced malignant lymphoma; one of them had grade 1 impairment already at baseline and 
progressed to grade 2 after chemotherapy. No neutropenia was seen in any dog. All dogs with 
Table 1 Gastrointestinal adverse effects after patupilone treatment as classified by VCOG-
CTCAE v1.0.
18
  
Dose Dose Dogs                 
 
Group 
 
(mg/m
2
)  (n) 
 
Diarrhea 
 
Anorexia 
 
Nausea 
 
Vomiting 
        
Grade 
1+2 (n) 
Grade 3 
(n) 
  Grade 
1+2 (n) 
Grade 
3 (n) 
  Grade 
1+2 (n) 
Grade 
3 (n) 
  Grade 
1+2 (n) 
Grade 
3 (n) 
1 1.6 1 
 
1 0 
 
1 0 
 
1 0 
 
1 0 
2 1.9 3 
 
2 0 
 
2 0 
 
2 0 
 
2 0 
3 2.3 3 
 
2 0 
 
2 0 
 
2 0 
 
0 0 
4 2.76 6 
 
3 0 
 
2*** 0 
 
3 0 
 
5 0 
5 3.3 3 
 
1 1 
 
0 2 
 
2 0 
 
2 0 
6 3* 4 
 
4** 0 
 
2*** 1 
 
3 0 
 
4 0 
Total   20   14 1 
 
9 3 
 
13 0 
 
14 0 
AE: adverse effects 
  
increase in alanine aminotransferase (ALAT) had received steroids for a prolonged period of time 
before study entry. Three dogs showed grade 3 increase in ALAT already at baseline and three 
dogs showed improvement or normalization of ALAT values at the end of chemotherapy.  
Gastrointestinal:  Main AE in this study were diarrhea, anorexia, nausea, and vomiting. Dose-
limiting AE was determined to be anorexia and diarrhea. In affected dogs, diarrhea started with a 
median of four days after chemotherapy. Upon occurrence of gastrointestinal AE after the first 
drug administration, supportive care was administered in 14/20 (70%) dogs. Not all AE were 
considered to be attributed to patupilone administration: in some dogs, toxicoses were considered 
to be attributed to disease progression or were considered to be due to treatment-unrelated co-
morbidities. However, all AE regardless of cause are listed in table 1.  
Other: Grade 1-2 fatigue was noted after 18/62 (29%) drug administrations. In two dogs grade 1 
fatigue was already present at study entry. A modified Karnofsky’s performance status score of 
1-2 was seen after 15/62 (24%) treatments. In two dogs however, a performance status of 1 was 
already recorded at baseline. No other AE were noted.  
 
 
 
 
 
 
 
 
 
  
 
Table 2 Metabolic adverse effects according to VCOG-CTCAE v1.0 after all 
60 evaluable drug administrations.
18 
  
Highest Toxicity Toxicities 
 
 Grade 
 
    
[occurrence of AE;                         
% of all administrations] 
Anemia 1 23 (38%) 
Thrombocytopenia 2 3 (5%) 
Neutropenia 0 0 (0%) 
Hypoalbuminemia 1 2 (3%) 
Increase in Alanine 
Aminotransferase 
3
a
 10 (17%) 
AE: adverse effects 
a
 Grade 3 toxicosis existed already at study entry. 
 
MTD. Patupilone was well tolerated up to a dose of 2.76 mg/m
2
. At the next higher dose level of 
3.3 mg/m
2
, two dogs showed dose-limiting grade 3 anorexia or anorexia and diarrhea, 
respectively. Dose was reduced by 10% to approach the optimal dose more precisely. At 3 
mg/m
2
, only one dog showed dose-limiting AE but the second application of chemotherapy had 
to be delayed for one week in two of the other dogs treated at this dose level due to grade 2 
diarrhea or grade 2 diarrhea and anorexia, respectively. Therefore, MTD for one cycle of 
patupilone was determined to be 2.76 mg/m
2
. 
Tumor Response Assessment.  Response was evaluated in 18/20 dogs. At the end of all 
patupilone treatments (range 1-7), three dogs (16.7%) showed PR, six dogs (33.3%) SD, and nine 
  
PD (50%). The 3/11 dogs receiving more than one treatment cycle showed partial remission in 
the short period of observation and included a dog with prostate carcinoma and two dogs with 
anaplastic mammary carcinoma and sublumbar lymph node metastases. In the latter, surgical 
excision of the primary tumor was performed two weeks prior to study entry. Both dogs showed 
recurrence at the site of surgery and experienced PR after administration of more than two 
patupilone administrations.  
 
Discussion 
According to this phase I trial, the administration of patupilone up to an IV dose of 2.76 mg/m
2 
was found to be safe in dogs with spontaneously occurring tumors and no hypersensitivity 
reactions were observed. This is in contrast to taxoid MSA such as paclitaxel and docetaxel 
where the use in dogs is limited due to the requirement of organic solvents that cause unwanted 
side effects even in dogs that are heavily pre-medicated.
24, 25, 26
 
In the in vitro part of this trial, canine tumor cells showed a strong decrease in proliferative 
activity with low doses of patupilone, (1nM and 0.2 nM in canine hemangiosarcoma and 
lymphoma cells, respectively), when compared to known patupilone-sensitive and -resistant 
human cell lines.
23
 In humans, a patupilone dose of 10 nM is considered to be an in vitro 
approximation of plasma levels at a MTD of 2.5 mg/m
2
.
6, 27
 In an in vivo model with human 
colon tumor xenografts patupilone administration resulted in high concentration in tumor tissue at 
168 hours after chemotherapy, while other tissues showed decreased concentrations.
22
 The 
presence of continuous drug exposure might contribute to tumor cell cytotoxicity and add to the 
prior described antiangiogenic efficacy of the drug.
6, 23, 28
 The MTD for two patupilone IV 
administrations given once weekly is 2.76 mg/m
2
, comparable to the dose in human patients for 
weekly administration.
29
 If patupilone is given at longer intervals, a higher dose is tolerated in 
  
man, as the severity of gastrointestinal signs can be controlled by proactive, aggressive diarrhea-
management.
30
 However, the main goal of this trial was to find MTD after one treatment cycle of 
patupilone (two administrations). One reason for the chosen schedule of two administrations 
aimed at being able to exploit not only the cytotoxic effect of the drug but also make use of the 
antiangiogenic and antivascular effects of epothilone B. Agents with antiangiogenic effects exert 
their efficacy after repeated administration of low doses with short interval in between, for 
example daily or weekly treatment.
31
 A second reason for this schedule was the intention to use 
the drug as a radiosensitizer in combined treatment with ionizing radiation. Epothilones are 
considered to be optimal radiosensitizing drugs as they induce cell cycle block in the most 
radiosensitive G2/M-phase already at low and non-cytotoxic doses. This led to additive or even 
supraadditive effect on tumor growth in mice with human cancer xenografts.
23, 32, 33
  
Hematological AE were generally mild and no neutropenia was seen. One treatment cycle of 
patupilone is therefore not associated with clinically significant myelosupression in dogs. The 
clinically relevant toxicosis in this study (≥ grade 2) was gastrointestinal, seen in 50% of all 
patients with main AE anorexia and/or diarrhea. However, in six dogs, mild pretreatment 
gastrointestinal impairment existed at study entry and might have had an effect on occurrence and 
severity of AE. Not all AE were considered to be due to the study drug, however, differentiation 
between drug-associated and drug-unrelated toxicosis is difficult, and therefore all AE were listed 
regardless of suspected cause. This toxicity profile resembles the one in human patients but in 
contrast to humans, no peripheral neuropathy was noted after up to seven patupilone 
administrations.
30
 Pathogenesis of neuropathy in chemotherapeutics that target microtubules is 
not entirely clear but can be explained by the disturbance of microtubule function and 
interference of the axonal transport.
34
 Although no neurological AE were noted in this study with 
  
a median of 3 patupilone administrations, mild symptoms might have been overlooked and 
cumulative toxicosis could occur.   
75% of the dogs received either steroids or NSAIDs. These drugs have a possible antitumor 
effect in certain tumor types, such as steroids in malignant lymphoma and NSAIDs in transitional 
cell carcinoma of the bladder and prostate carcinoma.
35, 36
 Most dogs experienced disease 
progression while under these drugs before study entry. However, in four dogs these substances 
were prescribed shortly before inclusion into the study. A possible positive influence on response 
due to these drugs cannot be excluded in these cases.  
This study was a dose-escalating trial; therefore many animals received low dosages of 
patupilone and most of the dogs were heavily pretreated and suffered from advanced disease 
state. Therefore response assessment was not a primary goal of this trial. A limitation of this 
study was the short observation of response and the lack of a defined period of time in order to 
count as a response. But partial remission in tumors that are difficult to treat (prostate and 
anaplastic mammary carcinoma) was unexpected and was interpreted as promising. 
Patupilone is a new antineoplastic agent with a manageable toxicity profile and a promising 
antitumor response in dogs with spontaneously occurring tumors. As patupilone induces an arrest 
at the most radiosensitive phase of cell cycle (G2/M), it is an ideal radiosensitizer showing supra-
additive efficacy in mice.
2, 23, 32, 33
 Furthermore, patupilone possesses antimetastatic and 
antiangiogenic properties, is able to cross the blood brain barrier and is not susceptible to p-
glycoprotein-overexpression-mediated chemoresistance.
2, 37
 This makes it a promising agent for 
single and combined modality treatment.   
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